Literature DB >> 12148849

Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck.

Douglas B Chepeha1, Paul T Hoff, Rodney J Taylor, Carol R Bradford, Theodoros N Teknos, Ramon M Esclamado.   

Abstract

OBJECTIVE: Our objective was to determine the proportion of patients disease free in the neck, with the primary site controlled, who have been treated with a selective neck dissection (SND) for squamous cell carcinoma (SCCa) of the upper aerodigestive tract, and who had cervical metastasis less than 3 cm. STUDY
DESIGN: A cohort of patients who fit the inclusion/exclusion criteria was identified retrospectively. Then all surviving patients were followed for a minimum of 2 years.
METHODS: A group of 52 patients who had 58 selective neck dissections for cervical metastases from SCCa of the upper aerodigestive tract were identified. The mean age was 56 years (range, 20-85 y), there were 40 males and 12 females, and mean follow-up was 24.5 months (range, 1-64 mo). Twenty-six patients had clinically negative (cNo) neck examinations and 26 had clinically positive neck examinations. Postoperative radiation was given for extracapsular spread, greater than 2 positive nodes, T3, T4, or recurrent disease if the patient had not received radiation before surgery. These radiation criteria excluded 18 patients from postoperative radiation treatment.
RESULTS: Kaplan-Meier survival analysis showed that the regional control rate with the primary site controlled was 0.94. Six patients developed recurrent neck disease. Three of these 6 patientswere surgically salvaged. Four recurrences were in the dissected field and 2 were out of the dissected field (level V).
CONCLUSIONS: With similar indications for radiation therapy, the regional control rate in this cohort is comparable to control rates obtained with modified radical neck dissection.

Entities:  

Mesh:

Year:  2002        PMID: 12148849     DOI: 10.1097/00005537-200203000-00005

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

Review 1.  Management of cervical metastasis.

Authors:  Eric J Lentsch
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Head and neck cancer: an evolving treatment paradigm.

Authors:  David M Cognetti; Randal S Weber; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  Outcomes in squamous cell carcinoma with advanced neck disease.

Authors:  James A Keir; Olivia J H Whiteside; Stuart C Winter; Sushir Maitra; Rogan C Corbridge; Graham J Cox
Journal:  Ann R Coll Surg Engl       Date:  2007-10       Impact factor: 1.891

4.  Are We Over-treating Neck in Buccal & Alveolo-buccal Cancers: Experience from a Tertiary Cancer Care Center.

Authors:  S V S Deo; N K Shukla; Deepak Jha; Paras Khanna; Archit Pandit; Sanjay Thulkar
Journal:  Indian J Surg Oncol       Date:  2012-08-11

5.  Selective use of postoperative neck radiotherapy in oral cavity and oropharynx cancer: a prospective clinical study.

Authors:  Miguel Martínez Carrillo; Isabel Tovar Martín; Ildefonso Martínez Lara; José Mariano Ruiz de Almodóvar Rivera; Rosario Del Moral Ávila
Journal:  Radiat Oncol       Date:  2013-04-28       Impact factor: 3.481

6.  Primary intraosseous carcinoma in the pediatric and adolescent mandible.

Authors:  Hyun Jun Oh; Dong Whan Shin; Hye-Jung Yoon; Hoon Myoung; Soung Min Kim
Journal:  World J Surg Oncol       Date:  2022-01-27       Impact factor: 2.754

7.  Focus issue: neck dissection for oropharyngeal squamous cell carcinoma.

Authors:  Kathryn M Van Abel; Eric J Moore
Journal:  ISRN Surg       Date:  2012-01-15

8.  Radical versus supraomohyoid neck dissection in the treatment of squamous cell carcinoma of the inferior level of the mouth.

Authors:  Abrão Rapoport; Daniel Kanabben Ortellado; Ali Amar; Carlos Neutzling Lehn; Rogério Aparecido Dedivitis; Ricardo Salinas Perez; Helen Mara Rodrigues
Journal:  Braz J Otorhinolaryngol       Date:  2007 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.